- Home
- AMS vs BLRX Comparison
AMS vs BLRX Comparison
Compare AMS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMS | BLRX |
|---|---|---|
| Founded | 1980 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 12.6M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | AMS | BLRX |
|---|---|---|
| Price | $2.21 | $2.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 9.4K | ★ 15.9K |
| Earning Date | 11-13-2025 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,423,000.00 | $12,735,000.00 |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.84 | N/A |
| 52 Week Low | $2.01 | $2.30 |
| 52 Week High | $3.11 | $7.77 |
Technical Indicators
Market Signals| Indicator | AMS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 63.85 | 45.32 |
| Support Level | $2.09 | $2.90 |
| Resistance Level | $2.15 | $3.20 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.28 | 20.00 |
Price Performance
Historical ComparisonAbout AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.